These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9615120)

  • 1. [Drug surveillance and topical drugs].
    Roujeau JC
    Ann Dermatol Venereol; 1996; 123(10):624-5. PubMed ID: 9615120
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmaco-surveillance of drug-induced cutaneous accidents].
    Barbaud A; Tréchot P; Schmutz JL
    Ann Dermatol Venereol; 1997; 124(6-7):474-5. PubMed ID: 9739914
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cutaneous side-effects in drug assessment].
    Jean-Pastor MJ
    Therapie; 2002; 57(3):265-8. PubMed ID: 12422540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatology-related postmarketing study commitments to the Food and Drug Administration.
    Bognet RA; Chiang DS; Katz KA
    J Am Acad Dermatol; 2006 Oct; 55(4):721-3. PubMed ID: 17010760
    [No Abstract]   [Full Text] [Related]  

  • 5. [Topical drug vehicles--influence of galenics in the therapy of atopic eczema].
    Daniels R
    Med Monatsschr Pharm; 2008 Apr; 31(4):139-43. PubMed ID: 18497245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.
    Saggar S; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(3):171-80. PubMed ID: 17687682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 8. Should new drugs be avoided?
    Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
    [No Abstract]   [Full Text] [Related]  

  • 9. Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents.
    Krejci-Manwaring J; McCarty MA; Camacho F; Carroll CL; Johnson K; Manuel J; Balkrishnan R; Hartle J; Fleischer A; Feldman SR
    J Am Acad Dermatol; 2006 May; 54(5 Suppl):S235-6. PubMed ID: 16631951
    [No Abstract]   [Full Text] [Related]  

  • 10. Issues in bringing new drugs to the market.
    Ansbacher R
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16322437
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 12. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 13. What's happening with pharmaceuticals? And how will it impact your practice?
    Williams B
    Tenn Med; 2005 May; 98(5):213-6. PubMed ID: 15934528
    [No Abstract]   [Full Text] [Related]  

  • 14. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].
    Selbmann HK
    MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776
    [No Abstract]   [Full Text] [Related]  

  • 15. [Illegal drug trade discovered in Bavaria. How can we protect ourselves from drug falsification?].
    Schweim HG
    MMW Fortschr Med; 2005 Sep; 147(38):11. PubMed ID: 16218221
    [No Abstract]   [Full Text] [Related]  

  • 16. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 17. [Drug safety. Notes about surveillance].
    Moreno Alvarez PJ; Madurga Sanz M
    Farm Hosp; 2004; 28(3):225-8. PubMed ID: 15222877
    [No Abstract]   [Full Text] [Related]  

  • 18. The drug safety review process.
    Somberg J
    Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
    [No Abstract]   [Full Text] [Related]  

  • 19. Postmarketing drug dosage changes.
    Peck CC
    Pharmacoepidemiol Drug Saf; 2003; 12(5):425-6. PubMed ID: 12899120
    [No Abstract]   [Full Text] [Related]  

  • 20. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.